Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S A Baughman

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Angiology|February 1, 1988
Elephantiasis nostras--a case reportS A Baughman, J Beninson
Journal of the American Academy of Dermatology|December 1, 1989
Evaluation of the adult carrier state in juvenile tinea capitis caused by Trichophyton tonsuransD E Babel, S A Baughman
Journal of Cardiovascular Pharmacology|June 1, 1995
Pharmacokinetics and pharmacodynamics of TP-9201, a GPIIbIIIa antagonist, in rats and dogsN B Modi, S A Baughman, B D Paasch, et al.
Journal of Cardiovascular Pharmacology|January 1, 1996
Pharmacokinetics and pharmacodynamics of TP-9201, a gpIIbIIIa antagonist, administered in combination with recombinant tissue-type plasminogen activator, heparin, and aspirin in beaglesN B Modi, T Reynolds, S A Baughman, et al.
Breast Disease|February 3, 2005
Genentech and breast cancer advocacyS Shak, R Bales, S A Baughman, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 20, 2000
Tissue disposition and pharmacokinetics of recombinant human nerve growth factor after acute and chronic subcutaneous administration in monkeysC B Nguyen, L Harris, E Szönyi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 1998
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatmentM D Pegram, A Lipton, D F Hayes, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Angiology|February 1, 1988
Elephantiasis nostras--a case reportS A Baughman, J Beninson
Journal of the American Academy of Dermatology|December 1, 1989
Evaluation of the adult carrier state in juvenile tinea capitis caused by Trichophyton tonsuransD E Babel, S A Baughman
Journal of Cardiovascular Pharmacology|June 1, 1995
Pharmacokinetics and pharmacodynamics of TP-9201, a GPIIbIIIa antagonist, in rats and dogsN B Modi, S A Baughman, B D Paasch, et al.
Journal of Cardiovascular Pharmacology|January 1, 1996
Pharmacokinetics and pharmacodynamics of TP-9201, a gpIIbIIIa antagonist, administered in combination with recombinant tissue-type plasminogen activator, heparin, and aspirin in beaglesN B Modi, T Reynolds, S A Baughman, et al.
Breast Disease|February 3, 2005
Genentech and breast cancer advocacyS Shak, R Bales, S A Baughman, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 20, 2000
Tissue disposition and pharmacokinetics of recombinant human nerve growth factor after acute and chronic subcutaneous administration in monkeysC B Nguyen, L Harris, E Szönyi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 1998
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatmentM D Pegram, A Lipton, D F Hayes, et al.
Pageof 1